De Wildt
Michiel Wouter De Wildt, Den Bosch NL
Patent application number | Description | Published |
---|---|---|
20150043714 | SIMULATED SPATIAL LIVE VIEWING OF AN OBJECT FROM VARIABLE VIEW-POINTS - The present invention relates to simulated spatial live viewing of an object. In order to provide spatial information to the user with reduced requirements concerning to maintain a particular position e.g. with respect to a 3D display or to wear or activate additional components, such as 3D glasses, it is provided to generate an electron beam ( | 02-12-2015 |
Rudolf Maria De Wildt, Hertfordshire GB
Patent application number | Description | Published |
---|---|---|
20110212168 | COMPOSITION FOR TARGETING DENDRITIC CELLS - The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma. | 09-01-2011 |
20110257373 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR DC-SIGN - The present invention disclosure provides an anti-dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN; CD209) immunoglobulin single variable domain. Polypeptides, ligands and compositions comprising such anti-DC-SIGN immunoglobulin single variable domains are also described along with nucleic acids encoding such immunoglobulins and vectors and host cells for expression. The invention disclosure further relates to uses, formulations, compositions and devices comprising such DC-SIGN-binding agents. | 10-20-2011 |
Rudolf Maria De Wildt, Stevenage GB
Patent application number | Description | Published |
---|---|---|
20120129778 | LIGAND THAT BIND TGF-BETA RECEPTOR RII - The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. The disclosure also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signaling and a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis. | 05-24-2012 |
20130045895 | BINDING DOMAINS - The invention relates to amino acid residues within an immunoglobulin light chain amino acid sequence (V | 02-21-2013 |
20140341971 | COMPOSITION FOR TARGETING DENDRITIC CELLS - The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma. | 11-20-2014 |
Rudolf M.t. De Wildt, Hertfordshire GB
Patent application number | Description | Published |
---|---|---|
20110159003 | Ligands That Bind Il-4 and/or Il-13 - Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described. | 06-30-2011 |
Rudolf M T De Wildt, Stevenage GB
Patent application number | Description | Published |
---|---|---|
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
Rudolf M. T. De Wildt, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20110236380 | LIGANDS THAT BIND IL-13 - Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL-13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells. | 09-29-2011 |
Thomas Gerardus Martinus De Wildt, Eindhoven NL
Patent application number | Description | Published |
---|---|---|
20090303075 | METHOD AND APPARATUS FOR SETTING THE STATE OF OPERATION OF AN APPLIANCE - An apparatus for setting the state of operation of an appliance ( | 12-10-2009 |